Lipella Pharmaceuticals (LIPO) announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office, or ...
Chalet Tan is a professor in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (TN, USA). Her lab focuses on targeted drug delivery, specifically biologics ...
Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, Oct. 15, 2024 (GLOBE NEWSWIRE) -- ...
As part of the first-in-human trial, participants received more than 15 times the standard dose of the chemotherapy drug doxorubicin every 21 days for up to one year. “Usually, a patient can only ...
Comprehensive Analysis Examines Liposomal NMN Delivery, Dosage Research Context, Third-Party Verification Standards, and What ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback